Roche And Transgene Partner On Therapeutic Vaccine For HPV-Related Diseases
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal has “potential to expand and evolve into an integrated personalized medicine approach” to HPV-mediated diseases, Roche tells “The Pink Sheet” DAILY.
You may also be interested in...
Transgene Loses Roche As A Partner But Stays The Course On Strategy
Roche backed out of a development deal with Transgene for a therapeutic vaccine, but the French drug developer says the implications, at least for the short term, are minimal.
Transgene Loses Roche As A Partner But Stays The Course On Strategy
Roche backed out of a development deal with Transgene for a therapeutic vaccine, but the French drug developer says the implications, at least for the short term, are minimal.
Transgene Plans Stock Offering Up To €150 Million And Profitability By 2015
Transgene to raise more capital following the granting of an exclusive option on its lead product to Novartis.